All In Biotech

NDA 210861 · Bayer Hlthcare

Vitrakvi

Larotrectinib Sulfate · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 26, 2018

Approved uses

3

Original approval plus efficacy supplements

Registered trials

21

0 Phase 3, 8 recruiting

FAERS reports

896

668 serious, 163 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 22, 2026.

VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test [see Dosage and Administration (2.1) ]. VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test. ( 1 , 2.1 )

Mechanism: Larotrectinib is an inhibitor of the tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. In a broad panel of purified enzyme assays, larotrectinib inhibited TRKA, TRKB, and TRKC with IC 50 values between 5-11 nM. One other kinase TNK2 was inhibited at approximately 100-fold higher concentration. TRKA, B, and C are encoded by the genes NTRK1, NTRK2, and NTRK3. Chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 9, 2025 Supplement 12 · Efficacy OrphanLetterLabel
  • Mar 25, 2021 Supplement 4 · Efficacy Letter
  • Nov 26, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelReviewLetter
2 products under this application
  • VITRAKVI · LAROTRECTINIB SULFATE EQ 100MG BASE · CAPSULE, ORAL · Prescription
  • VITRAKVI · LAROTRECTINIB SULFATE EQ 25MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Larotrectinib" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness62
  • fatigue62
  • drug ineffective61
  • death52
  • neuropathy peripheral45
  • pain44
  • disease progression38
  • nausea38
  • off label use38
  • myalgia27
  • vomiting27
  • diarrhoea23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201997
2020138
2021147
2022137
2023138
202493
2025100
202646

Recalls

1 FDA enforcement reports for this application.

  • Nov 6, 2023 · Class I · Terminated

    Microbial Contamination of Non-Sterile Products: microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vitrakvi (Larotrectinib Sulfate)

2024 spending

$40.7M

Beneficiaries

180

1,096 claims

Per beneficiary

$225,932

$550.95 per unit

View as table
YearSpending
2020$7,400,574
2021$17,432,265
2022$22,001,911
2023$29,548,699
2024$40,667,723

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.